# Nanjing Haina Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nanjing-haina-medical-technology-co

- Industry: Pharmaceuticals
- Headquarters: Nanjing, China
- Website: www.healthnice.net
- Total disclosed funding: $15M
- Latest round: Series B (Aug 12, 2022)
- Investors on record: 1

## About

Established in 2001 and based in Nanjing, China, Nanjing Haina Medical Technology Co.,Ltd. operates as a pharmaceutical developer that provides new drug development process services. The company's R & D area has exceeded 5000 square meters and the investment exceeds CNY 400 million. The R&D team divides into synthesis department, preparation department and analysis department. Nanjing Healthnice Pharmaceutical Technology Co.,Ltd., Nanjing Oceanwide Pharmaceutical Technology Co., Ltd. and Nanjing Yinuo Pharmaceutical Technology Co., Ltd. are the subsidiary of the company. Boda medicine has become the strategic partner of the company in July 2021. In March 2025, Chengdu Pioneer Drug Development Co., Ltd. announced to acquire a majority stake in Nanjing Haina Medical Technology Co.,Ltd. The business of the company includes new drug discovery, pharmaceutical and clinical research, biological sample detection. The company's products and services include contract development and manufacturing organization (CDMO) services, consistency evaluation, technology transfer, technical service and clinical services. Consistency evaluation includes oral solid preparation and injection consistency evaluation. Technology transfer includes transfer of clinical approval documents for guanfaxin hydrochloride raw materials and tablets, transfer of clinical approval documents for fluconazole raw materials and liniments, transfer of clinical approval documents for pirepanide raw materials and tablets. The company's R&D platforms include drug synthesis platform, drug preparation platform impurity analysis, impurity analysis platform and pharmacokinetic research platform. Impurity analysis platform includes study on genotoxic impurities, synthesis, separation and preparation of impurities. The company’s revenue is generated by providing services and integrated solutions for the entire process of new drug development.

## Funding rounds

- Series B, Aug 12, 2022, $15M — Jiangsu Jincai Investment

## Investors

- Jiangsu Jincai Investment (https://capitalatlas.ai/funds/jiangsu-jincai-investment) — Series B